Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28947751 | 0.80 | AR (0.47) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL22816825 | 0.80 | FFAR1 (0.47) | AR | |
| SCHEMBL323502 | 0.79 | KDM4E (0.51) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL20930791 | 0.79 | KCNJ1 (0.39) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL7660043 | 0.79 | KCNJ1 (0.39) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL8120210 | 0.79 | KCNJ1 (0.39) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL21230254 | 0.79 | KCNJ1 (0.39) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL3020737 | 0.79 | SLC22A12 (0.41) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL18189524 | 0.79 | IDH1 (0.50) | ARKCNJ1KCNH2SLC22A12IDH1 | |
| SCHEMBL29993215 | 0.79 | KCNJ1 (0.39) | ARKCNJ1KCNH2SLC22A12IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) | 2023-09-19 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-10934278-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20210032181-A1 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3490977-B1 | CYCLOBUTANE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED POTASSIUM CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2089373-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934278-B2 | Compounds | KCNA3, KCNN3, KCND3 | AR 3581/4885KCNJ1 52/4885KCNH2 24/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | AR 4850/4885KCNJ1 34/4885KCNH2 14/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | AR 4850/4885KCNJ1 34/4885KCNH2 14/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | AR 670/4885KCNJ1 4521/4885KCNH2 3208/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | AR 1307/4885KCNJ1 2802/4885KCNH2 407/4885 |
| US-20210032181-A1 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME | AFF2, AFF4, AFF1 | AR 1185/4885KCNJ1 3587/4885KCNH2 3584/4885 |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | AFF2, AFF4, AFF1 | AR 1185/4885KCNJ1 3587/4885KCNH2 3584/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | AR 189/4885KCNJ1 2042/4885KCNH2 1142/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | AR 4850/4885KCNJ1 34/4885KCNH2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.